Takeda Drives Continued Scientific Leadership Through Real-World Evidence in Rare Hematological Diseases at ASH 2021
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced the presentation of nine company-sponsored abstracts at the 63rd American Society of Hematology (ASH) Annual Meeting being held December 11-14, 2021 in Atlanta, Georgia and virtually. The abstracts span Takeda’s extensive hematology portfolio and research and development (R&D) pipeline, featuring…